Caption Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Caption Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30,000	Closed	-$4.59M	–	1686
2021 Q1	$4.59M	Hold	30,000	–	–	0.1%	268
2020 Q4	$4.69M	Sell	30,000 -25,000	-45%	-$3.21M	0.11%	240
2020 Q3	$6.29M	Buy	+55,000	New	+$5.93M	0.15%	167
2020 Q2	–	Sell	-49,000	Closed	-$4.4M	–	1267
2020 Q1	$4.4M	Buy	49,000 +14,000	+40%	+$1.37M	0.25%	114
2019 Q4	$3.79M	Buy	35,000 +10,000	+40%	+$1.07M	0.13%	220
2019 Q3	$2.45M	Sell	25,000 -15,000	-38%	-$1.69M	0.13%	205
2019 Q2	$5.24M	Buy	+40,000	New	+$5.16M	0.26%	110

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Caption Management's ALXN Position: Q2 2021 in Review

Caption Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 18,200 shares — an estimated $2.78M sold.

Caption Management first reported a position in ALXN in Q2 2019 and held it in 8 quarters. The position peaked at $13.4M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Caption Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Caption Management sold 18,200 Alexion Pharmaceuticals shares in Q2 2021, an estimated $2.78M.
Caption Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 8 quarters.
Caption Management's Alexion Pharmaceuticals position peaked at $13.4M in Q4 2020.
708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Caption Management's 13F filing for Q2 2021, filed 16 Aug 2021.